This seems to have a fundamental importance irrespective of its possible relevance to Covid-19. That triiodothyronine (liothyronine/T3) treatment might have therapeutic indications other than in hypothyroidism. But it also makes me wonder whether those who have relevant disorders might do worse, much worse, if they are even slightly hypothyroid.
Clin Hemorheol Microcirc . 2021 Jun 11.
doi: 10.3233/CH-211215. Online ahead of print.
Acute triiodothyronine treatment and red blood cell sedimentation rate (ESR) in critically ill COVID-19 patients: A novel association?
Constantinos Pantos 1 , Vassiliki Apostolaki 2 , Leonidas Kokkinos 2 , Athanassios Trikas 3 , Iordanis Mourouzis 3
Affiliations
• PMID: 34151781
• DOI: 10.3233/CH-211215
Abstract
Sepsis and septic shock result in impaired microcirculation and red blood cell rheology which lead to tissue hypoxia and multi-organ failure. Early administration of triiodothyronine prevents tissue hypoxia in experimental sepsis. In this context, a clinical trial was initiated to test the efficacy of acute triiodothyronine administration to combat tissue hypoxia in critically ill COVID19 patients. Here, we provide preliminary data from interim analysis of this study showing a novel acute effect of triiodothyronine on erythrocyte sedimentation rate which may have an important therapeutic impact on red blood cell rheology and tissue hypoxia in sepsis and particular in COVID19 critical illness.
Trial registration: ClinicalTrials.gov, NCT04348513. Registered 16 April 2020, clinicaltrials.gov/ct2/show....
Keywords: COVID19; Thyroid hormone; erythrocyte sedimentation rate; hemorheology; hypoxia; microcirculation.
Associated data
• ClinicalTrials.gov/NCT04348513
